

Cognetivity Neurosciences to List on Frankfurt Stock Exchange

VANCOUVER, May 3, 2018 /CNW/ - Cognetivity Neurosciences Ltd. ("CGN", or the "Company"), (CSE: CGN), a Vancouver-based healthcare technology company, is pleased to announce its listing on the Frankfurt Stock Exchange under the trading symbol "IUB" on May 3, 2018.

The Frankfurt Exchange ranks third globally in terms of volume of trading behind New York and NASDAQ and will provide CGN broader access to European and other international investors.

"Our goal is to create increasing value for our shareholders. The Frankfurt Stock Exchange is another exciting component of our public market strategy and will make it easier for European investors to get involved in the Cognetivity story. The Frankfurt Stock Exchange accounts for over 90% of the volume of all German stock exchanges and represents a large share of the European market, so is ideal to allow us to reach a new and active investor base." Stated CEO and Director, Sina Habibi.

The Frankfurt Stock Exchange has more than 250 international trading institutions and more than 4,500 traders. Investors directly connected to the Frankfurt Stock Exchange represent 35% of the world's investment capital. A listing in Frankfurt will also provide a tax advantage to German investors.

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity's ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.

For more information please visit – www.cognetivity.com

ON BEHALF OF THE BOARD

"Sina Habibi"

Sina Habibi
Chief Executive Officer and Director

FORWARD LOOKING STATEMENTS:

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

The Exchange does not accept responsibility for the adequacy or accuracy of this release

SOURCE Cognetivity Neurosciences Ltd

View original content: <http://www.newswire.ca/en/releases/archive/May2018/03/c5543.html>

%SEDAR: 00039034E

For further information: Email: info@cognetivity.com; For media enquiries contact: Josh Stanbury, Email: josh@sjspr.co.uk

CO: Cognetivity Neurosciences Ltd

CNW 09:00e 03-MAY-18